Urothelial Cancer Awareness Month

Featured

Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel

This article demonstrates the long-term effectiveness of UGN-101 in treating low-grade upper tract urothelial carcinoma. The findings highlight the potential for durable responses and reduced recurrence rates, offering valuable insights for improving patient care and treatment strategies.

  • The Journal of Urology
  • March 2025
Read More

Diagnosis

Differences in the expression heterogeneity of ADC-related markers between primary tumors and metastatic lymph nodes in advanced urothelial cancers.

This article explores the expression patterns and heterogeneity of ADC-related genes in advanced urothelial cancers, which are crucial for inhibiting tumor progression. The findings highlight the need for targeted therapies based on gene expression in both primary and metastatic tissues, potentially improving treatment outcomes and patient prognosis.

  • Journal of Clinical Oncology
  • August 2024
Read More

Germline genetic variants in cancers of the bladder, renal pelvis, ureter, or urethra.

This article highlights the prevalence of pathogenic germline variants in urothelial carcinoma (UC) patients and their association with poorer outcomes in muscle-invasive UC. It underscores the need for genetic testing in all UC patients to guide personalized treatment and calls for further research into variants of unknown significance (VUS) in diverse populations.

  • Journal of Clinical Oncology
  • May 2024
Read More

Real world effectiveness of systemic treatment in patients (pts) with advanced upper tract urothelial carcinoma (UTUC) with histological variants.

This article highlights the efficacy of chemotherapy in the first-line setting and immune checkpoint inhibitors (ICIs) in pretreated advanced urothelial carcinoma with variant histology (UC-V) and non-urothelial carcinoma (NUC). It provides insights into treatment responses and safety, emphasizing the need for tailored therapeutic approaches based on histological variants.

  • Journal of Clinical Oncology
  • February 2025
Read More

Treatment

The biologic landscape and therapeutic implications of upper tract urothelial cancer

This article highlights the unique biological and clinical differences between upper tract urothelial cancer (UTUC) and bladder cancer, which can inform more precise treatment approaches. Additionally, it discusses emerging therapeutic options and the need for further trials specifically focused on UTUC, offering insights into improving patient outcomes.

  • Current Opinion in Urology
  • January 2025
Read More

Germline genetic variants in cancers of the urothelial tract and association with outcomes

This article highlights that germline pathogenic variants (PVs) are found in 18% of urothelial carcinoma (UC) patients, with Lynch syndrome being associated with upper tract tumors and favorable responses to immune checkpoint inhibitors (ICIs). It underscores the importance of genetic testing for all UC patients to guide personalized treatment plans and suggests further investigation into ICIs for early-stage UC in Lynch syndrome patients.

  • Journal of Clinical Oncology
  • February 2025
Read More

Immune checkpoint inhibitors (ICIs) in advanced upper tract urothelial cancer (UTUC) with mismatch repair deficiency (dMMR) or microsatellite instability (MSI).

Healthcare providers would find this article important because it demonstrates the remarkable efficacy of single-agent immune checkpoint inhibitors (ICIs) in treating advanced dMMR/MSI-H upper tract urothelial carcinoma (UTUC), with many patients achieving long-term remission. It provides insights into using dMMR/MSI-H as predictive and prognostic biomarkers, guiding more effective and personalized treatment strategies for this subpopulation.

  • Journal of Clinical Oncology
  • February 2025
Read More

Gold standard nephroureterectomy, chemoprophylaxis and surveillance in upper tract urothelial carcinoma

This article summarizes recent evidence on surgical management, strategies to reduce tumor recurrence, and surveillance regimens for upper tract urothelial carcinoma (UTUC). It provides insights into the benefits of minimally invasive surgery, the use of chemoprophylaxis, and the need for personalized follow-up strategies to improve patient outcomes.

  • Current Opinion in Urology
  • January 2025
Read More

Utilization of neoadjuvant chemotherapy (NAC) and pathologic outcomes in upper tract urothelial carcinoma (UTUC).

This article is important because it highlights the evolving use of neoadjuvant chemotherapy (NAC) in treating high-risk upper tract urothelial carcinoma (UTUC) and its significant response rates. It emphasizes the need for retroperitoneal lymph node dissection in staging and calls for improved care quality in non-academic settings and for patients living farther from treatment facilities.

  • Journal of Clinical Oncology
  • May 2024
Read More